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Abbreviations  
FLAIR = Fluid-attenuated inversion recovery;  
QSM = Quantitative susceptibility mapping;  
SVCD = small-vessel cerebrovascular disease; 
WMH = White matter hyperintensities.  
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Abstract 
The aging brain is characterized by an increased presence of neurodegenerative and vascular pathology. 
However, there is substantial variation regarding the relationship between an individual’s pathological 
burden and resulting cognitive impairment. To identify correlates of preserved cognitive functioning at 
highest age, the relationship between β-amyloid plaque-load, presence of small vessel cerebrovascular 
disease (SVCD), iron-burden and brain atrophy was investigated. 80 cognitively unimpaired participants 
(44 oldest-old, aged 85-96; 36 younger-old, aged 55-80) were scanned by integrated PET-MRI for 
assessing β-regional amyloid plaque-load (18F-Flutemetamol), white matter hyperintensities as an 
indicator of SVCD (FLAIR-MRI) and iron-load (Quantitative Susceptibility Mapping). For the oldest-old 
group, lower cortical volume, increased β-amyloid plaque-load, prevalence of SVCD and lower 
cognitive-performance in the normal range was found. However, compared to normal-old, cortical iron 
burden was lower in the oldest old. Moreover, only in the oldest-old, entorhinal cortex volume positively 
correlated with β-amyloid plaque-load. Our data thus indicate that the co-occurrence of aging-associated 
neuropathologies with reduced QSM-measures of cortical iron-load constitutes a lower vulnerability to 
cognitive loss.    
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Introduction 
While advanced age is associated with substantial brain change and increased risk for cognitive decline, 
several studies on populations of older adults have revealed high levels of cognitive functioning despite 
considerable brain pathology. The resilience against such pathologies can be described as the brain’s 
reserve; the cognitive and physiological properties that allow an individual to better tolerate age-related 
brain alterations and neuropathological burden before cognitive performance is impaired (Barulli and 
Stern, 2013). Alternatively, maintained cognitive functioning could be attributed not to reserve, but to the 
presence of neuroprotective factors such as genetic variants, or alterations in clearance mechanisms that 
prevent the accumulation of neuropathologies at high age (Nyberg et al., 2012). Individuals in the age-
group of 85 years and above ("oldest-old") are of particular interest when investigating both the 
relationship between manifest brain change and risk for Alzheimer's disease (AD) (Kawas et al., 2013), 
and potential physiological factors that promote resistance against age-related neuropathological burden 
(Nyberg et al., 2012; Rogalski et al., 2013). While Apolipoprotein E ε4 (APOE4) carrier-status is the 
strongest known risk factor for sporadic AD in the younger-old (Corder et al., 1993) and has been linked 
to increased β-amyloid plaque burden in the cognitively normal (Hollands et al., 2017), there also are 
reports suggesting no association of APOE4 status with incident dementia or compensatory reserve 
mechanisms in the oldest-old (Corrada et al., 2013; Garibotto et al., 2012). 
Several studies have reported substantial discrepancies between measurable neuropathology and expected 
cognitive performance. This includes increased levels of β-amyloid plaques, which may reflect risk for 
future cognitive decline due to AD (Kawas et al., 2013; Sperling et al., 2009) and can be measured in 
cognitively healthy older adults (Mintun et al., 2006). In addition, regional atrophy was linked to AD-
associated neurodegenerative brain change, typically affecting hippocampus and entorhinal cortex years 
before manifestation of cognitive decline (de Leon et al., 1989; Frisoni et al., 2010). The coexistence of β-
amyloid plaques with other non-AD specific neurodegenerative alterations could indicate the greatest risk 
for progression to cognitive decline (Jagust, 2016; Mormino et al., 2014). For example, small-vessel 
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cerebrovascular disease (SVCD) is a frequent finding in cognitively healthy older adults, and relates to 
pathogenic markers of AD including β-amyloid plaque burden and regional atrophy, thus increasing risk 
for cognitive dysfunction (Guzman et al., 2013). Cerebral accumulation of iron is another 
neuropathological finding associated with aging, but also with neurodegenerative disorders including AD 
(Ayton et al., 2015; Ayton et al., 2017). Local iron accumulations in the vicinity of β-amyloid plaques 
may reflect both oxidative stress (Andersen et al., 2014; Meadowcroft et al., 2009; Rottkamp et al., 2001) 
and presence of activated microglia (Zeineh et al., 2015). Additionally, activated proinflammatory 
microglia have been correlated to β-amyloid associated neurodegeneration and cognitive impairment (Fan 
et al., 2017; Serrano-Pozo et al., 2016), suggesting that in vivo measures of iron could indicate both 
oxidative stress and β-amyloid associated neurodegeneration (Ayton et al., 2017; Derry and Kent, 2017; 
van Bergen et al., 2016b).  
State-of the art neuroimaging using multiple imaging modalities can provide in vivo information on 
various neuropathological burdens. Radioactive tracers may be used for measuring cerebral β-amyloid 
plaque burden by Positron-Emission-Tomography (PET) (Klunk et al., 2004; Vandenberghe et al., 2010). 
T1 weighted MRI is an established measure for regional atrophy in AD (Frisoni et al., 2010) and SVCD 
severity can be inferred from white matter hyperintensities (WMH), as measured by Fluid-Attenuated 
Inversion Recovery (FLAIR) MRI (Guzman et al., 2013). Recent developments on quantitative 
susceptibility mapping (QSM) techniques (Deistung et al., 2013; Li et al., 2011; Lim et al., 2013; 
Schweser et al., 2012) allow for in vivo measures of cerebral iron-load.  
While research on oldest-old populations may significantly advance knowledge on both protective and 
risk factors in AD and other age-related cognitive disorders (Kawas et al., 2013), not much is known on 
mechanisms that determine the relationship between presence of major neuropathologies and preserved 
cognitive functioning in the oldest-old. Aims of the current study therefore were 1.) to assess prevalence 
of aging-related brain change in a population of cognitively healthy older adults by assessing cerebral β-
amyloid burden, differences in structural volume as an indicator of present neurodegenerative change, 
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cerebral iron-load and the regional distribution of WMH as a proxy of SVCD; 2.) to characterize brain-
physiology and neural mechanisms associated with preserved cognitive function, by assessing interactive 
relationships of pathological alterations and differences between cognitively healthy oldest-old and 
younger-old.  
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Methods 
Participants 
For the current study, two cohorts at the Hospital for Psychogeriatric Medicine and Institute for 
Regenerative Medicine (IREM), University of Zurich (UZH), Switzerland were combined resulting in a 
total sample of 80 healthy and cognitively unimpaired older adults. Within the recruited sample, two 
groups were compared: 36 "younger-old" (ages 55-80 years) and 44 "oldest-old" (ages 85-96 years) 
participants. Study procedures were in concordance with Human Research Act of Switzerland as well as 
with the declaration of Helsinki. Written informed consent was obtained from all participants before 
inclusion in the study. 
Inclusion criteria were: preserved everyday functioning and no significant cognitive impairment, as 
assessed by the CERAD neuropsychological battery (Sotaniemi et al., 2012) and additional tests used in 
earlier studies of ours (van Bergen et al., 2016b), including Mini Mental State Examination (MMSE), 
Verbal Learning and Memory Test (VLMT), Boston Naming Test (BNT), Trail Making Test B/A, and 
Stroop inference test. Exclusion criteria included: significant medication or drug abuse with possible 
effects on cognition, inability to partake MRI, MRI scans with the evidence of infection or infarction, 
clinically relevant changes in red blood cell count, serious medical or neuropsychiatric illness and 
significant exposure to radiation. 
MRI data acquisition 
All participants were scanned using a 3T GE SIGNA PET-MR whole-body scanner (GE Medical 
Systems, Milwaukee, WI, USA) equipped with an 8-channel head coil. T1-weighted BRAVO images 
(TI=450ms, voxel size=1x1x1mm3, flip-angle=12°, ASSET factor=2, scan time=6:00min) were acquired 
for anatomical referencing and automated image segmentation. MR phase measurements used for QSM 
calculation were acquired using a multi-echo 3D gradient recalled echo (GRE) sequence with 6 echoes 
(TR/TE1/∆TE=40/6/4ms, voxel size=1x1x1mm3, flip angle=15°, bandwidth=±62.5 kHz, flow 
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compensated, ASSET factor=2, scan time=7:53min). Phase data acquired with an echo time in the range 
of 18-26ms was used for QSM reconstruction. Images used to determine WMH were acquired using a 
CUBE FLAIR sequence (TR=6500ms, TE=134, ARC factor=2, voxel size=1x1x1.2mm3, 
bandwidth=±31.25 kHz, scan time=6:07min).  
Assessment of structure volumes 
To assess regional differences, the T1-weighted image was segmented using a multi-atlas matching 
approach consisting of 143 bilateral Regions of Interest (ROIs) developed as part of the Johns Hopkins 
University brain atlas. The atlas system is optimized for the parcellation of potential non-healthy brains 
by applying a Multiple-Atlas Likelihood Fusion algorithm and Ontology Level Control technology on the 
JHU multi-atlas sets (Djamanakova et al., 2014; Mori et al., 2016; Tang et al., 2013). Specifically, the 
atlas set of 26 participants aged between 50 and 90 years was used.  
To normalize different brain sizes across participants, individual structural volume was corrected with the 
following approach: Corrected structure volume = Original structure volume × (whole sample mean 
intracranial volume / participant intracranial volume) (van Bergen et al., 2016b). Twelve gray-matter 
ROIs were selected based on earlier reports on distribution of brain pathology at early stages of AD 
(Frisoni et al., 2010; Serrano-Pozo et al., 2011). 
ROI-masks were eroded with two pixels to account for partial volume effects before being used as a mask 
to analyze average iron-load (QSM), β-amyloid burden and WMH detection. These imaging volumes 
were first re-sliced to the individual’s T1 space, in which the atlas was defined, before further analysis. 
Quantitative susceptibility mapping (QSM) for measuring brain iron-load 
Multiple processing steps were performed to calculate from the acquired MR phase images the 
quantitative susceptibility maps of which local cerebral iron-load was assessed. First, phase unwrapping 
was performed using Laplacian based phase unwrapping (Li et al., 2011). A brain mask was then obtained 
by skull-stripping the GRE magnitude image acquired at TE of 14ms using FSL's brain extraction tool 
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(BET, FMRIB Oxford, UK). The unwrapped phase images were then divided by 2π*TE to obtain an 
image of the frequency shift in Hz for each echo. Subsequently, background fields were eliminated with 
the sophisticated harmonic artifact reduction for phase data (SHARP) (Schweser et al., 2011) approach 
using a variable spherical kernel size with a maximum radius of 4mm and a regularization parameter of 
0.05 (Schweser et al., 2011; Wu et al., 2012b). After removal of background fields, the resulting images 
of the three echoes were averaged to obtain a higher SNR as compared to single echo reconstruction (Wu 
et al., 2012a). Inverse dipole calculations to obtain the susceptibility maps were performed using an 
iLSQR based minimization (Li et al., 2015). The means of the standard deviations of susceptibility in 
commonly accepted QSM reference regions, such as various white matter bundles and sections of the 
cerebrospinal fluid, were evaluated to select the region with the lowest mean standard deviations as the 
reference region (Deistung et al., 2013). For clarity and consistency with earlier studies, changes in 
susceptibility values will be referred to as changes in iron-load, due to the previously demonstrated 
correlation of susceptibility values with tissue iron-load in brain gray matter (Deistung et al., 2013; Li et 
al., 2011; Lim et al., 2013; Schweser et al., 2012). 
Flutemetamol-PET for estimation of brain β-amyloid plaque burden 
Flutemetamol-PET was used to estimate individual local brain β-amyloid plaque burden (Vandenberghe 
et al., 2010). Individual dose of 140MBq of Flutemetamol was injected into the cubital vein. Time-of-
flight algorithm including necessary corrections were applied to reconstruct the PET-images. Standard 
MRAC images were used to derive attenuation correction maps according standard implemented 
algorithms. Late frame (minutes 85-105) values were standardized by the cerebellar gray matter value 
(Vandenberghe et al., 2010), resulting in 3D-volumes of Flutemetamol retention as an estimate of β-
amyloid burden via standard uptake value ratios (SUVR) (matrix=256x256x89, voxel 
size=1.2x1.2x2.78mm3).  
Single measures of individual cortical β-amyloid burden and iron-load were calculated for each 
participant based on average gray-matter ROI values of Flutemetamol-SUVR and susceptibility, 
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respectively, as reported earlier (van Bergen et al., 2016b). To determine "amyloid-positive" status the 
Flutemetamol-SUVR cutoff value of 1.562 was used (Vandenberghe et al., 2010). 
Assessment of SVCD by semi-automated WMH detection 
To assess occurrence of WMH, each participant’s FLAIR images were segmented into gray matter and 
white matter regions using the previously generated atlas. Parameters necessary for labeling atlas regions 
with WMH were determined by repeatedly manually optimizing the automated process. In a subset of 10 
randomly selected participants all white matter regions exhibiting WMH were manually labeled to create 
a training dataset. Of the 110 white matter regions defined by the atlas, regions smaller than 1 ml were 
excluded as they were found to not be validly labeled by the automated process when optimizing the 
algorithm by comparison to manual assessment. This resulted in a total of 42 white matter regions where 
automated labeling was consistent with manual labeling in the training dataset (average corrected 
structure volume and standard deviation 5.17 ± 1.70 ml). All gray matter regions were grouped together 
to extract the average gray matter intensity per participant. As demonstrated earlier (Iorio et al., 2013), 
presence of WMH in each white matter region was automatically identified by counting voxels with 
intensities 1.5 standard deviation above the average gray matter intensity of each participant. Finally, 
regions including more than 0.25 ml of voxels identified as representing WMH, were labeled as 
exhibiting WMH. The threshold of 0.25 ml was determined by comparing manual with automated 
labeling for maximizing specificity in the training dataset. Automated WMH assessment was finalized by 
manual validation of identified regions. This included adjustment of WMH counts when a region solely 
contained the edge of a single WMH while the core of that WMH was in another region. By summing the 
number of regions labeled as exhibiting WMH, a value indicating SVCD-burden was calculated for each 
participant.  
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Local correlation analysis 
For each of the selected ROIs, WMH score and regional volume were used as outcome variables with 
local β-amyloid burden and local iron-load as predictors, while controlling for age and gender. All 
correlation analyses were performed using Spearman’s rank correlation coefficient. To investigate 
differences in the correlation effects between oldest-old and younger-old, Fisher’s r-to-z transformation 
was applied on the correlation coefficients within each region for each group (Fisher, 1921). False 
Discovery Rate (FDR) correction for multiple testing (Benjamini and Hochberg, 1995) was applied to the 
p-values of all regions for each predictor-outcome pair and results were found significant when p-FDR-
corrected < 0.05. Two-sided t-tests were used for group comparisons. In case of non-normal distributed 
data, statistical tests for differences between groups were performed on log-transformed data. All 
statistical tests were performed in MATLAB R2016b (Mathworks, Natick, MA).  
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Results 
Characteristics of the studied populations and neuropsychological performance.  
Demographic information for the investigated study populations and neuropsychological test performance 
at time of inclusion are summarized in table 1. The average education level, as measured by years of 
formal education, was significantly lower in oldest-old compared to younger-old (oldest-old: 14.2 (2.8) 
years; younger-old: 15.9 (2.6), p=0.010). Clinical examination revealed self-reliance and absence of 
cognitive impairment in the oldest-old group. However, they performed significantly lower than the 
younger-old group in all administered neuropsychological tests except CERAD word list recognition 
(table 1B). Eleven out of 36 younger-old (31%) and six out of 44 oldest-old (14%) were APOE4 carriers. 
Fisher test on the odds ratio of an APOE4 carrier having oldest-old status resulted in a non-significant 
trend (p=0.071, CI=0.11-1.09). 
Prevalence of neuropathological burden in oldest- versus younger-old. 
While corrected structure volume in cortical gray matter regions and the hippocampus was significantly 
lower in oldest-old compared to younger-old, no significant difference could be observed for the 
entorhinal cortex (figure 1A, supplementary table 1A). The cutoff for Flutemetamol SUVR 
(Vandenberghe et al., 2010) identified eight oldest-old and five younger-old participants as "amyloid-
positive". Consistently, quantitative assessment of Flutemetamol SUVR indicated significantly higher 
regional β-amyloid plaque burden in the oldest-old than younger-old for all twelve investigated brain 
structures (figure 1B, supplementary table 1B). Deep frontal white matter was found to have the lowest 
average susceptibility standard deviations and was selected as a reference region to assess relative iron-
load for each participant. Interestingly, iron-load in the oldest-old was significantly lower in neocortical 
regions, insula and posterior cingulate. Only in the putamen was iron-load higher in oldest-old than the 
younger-old (figure 2, supplementary table 1C). As SVCD-burden was non-normally distributed, group 
comparisons were performed on log-transformed scores. Almost all oldest-old exhibited substantial 
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SVCD upon visual inspection, which is reflected by significantly higher (p=0.004) SVCD in oldest-old 
(6.59 ± 0.62) compared to younger-old (2.36 ± 0.29, supplementary table 1D). For assessment of effects 
accountable to age, a 1-way MANCOVA with age as covariate was used to compare neuropsychological 
test scores, volume, cortical β-amyloid burden, cortical iron and log-transformed SVCD-burden between 
oldest-old and younger-old. Here, no significant difference could be observed, when correcting for age. 
Relationship between β-amyloid burden, iron-load, structure volume and prevalence of SVCD. 
Significant correlations (p-FDR-corrected<0.05) in the whole sample were found between β-amyloid 
burden and structure volume in the amygdala; and between iron-load and structure volume in insula, 
entorhinal cortex and parietal cortex (table 2A). Prevalence of SVCD correlated with β-amyloid burden 
in the entorhinal cortex and frontal cortex. Moreover, SVCD correlated negatively with iron-load in the 
amygdala, entorhinal cortex, parietal cortex and the neocortex as a whole (table 2B). When testing 
APOE4 carriers separately, significant correlations between β-amyloid burden and SVCD (p=0.01 
r=0.80) and iron-load and volume (p=0.02 r=-0.60) could be observed in the entorhinal cortex. 
Group-specific correlations of structure volume with β-amyloid burden. 
Secondary, group specific regression-analysis indicated a significant correlation of high local β-amyloid 
burden with high structure volume in the entorhinal cortex of the oldest-old, which was not present in the 
younger-old (figure 3, oldest-old p=0.01 r=0.39, younger-old p=0.59 r=-0.09) and insula (oldest-old 
p=0.04 r=0.31, younger-old p=0.31 r=-0.18), significant difference of correlations was confirmed by 
Fisher’s r-to-z transformation (entorhinal cortex p=0.031, insula p=0.032). 
To identify potential effects of education level, correlation analysis was performed with local structure 
volume and local β-amyloid burden as outcome variables and years of education as predictor, while 
controlling for age and gender. No significant correlation with years of education was found in any of the 
structures (supplementary table 2).  
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Discussion 
By investigating a study population of cognitively unimpaired younger- and oldest-old by combined PET-
MRI, we found significantly higher prevalence of neuropathological burden in the oldest-old, as reflected 
by cerebral β-amyloid burden, reduced volume of structures and higher prevalence of SVCD. While 
neuropsychological testing indicated generally lower performance levels in the oldest-old, they did not 
show significant cognitive impairment. Differences in the oldest-old furthermore included lower iron-load 
in cortical regions and an association of high entorhinal volume with entorhinal β-amyloid burden. Our 
findings support earlier considerations that distinct physiological brain properties may allow for 
maintained high cognitive functioning in the oldest-old, despite present brain pathology (Barulli and 
Stern, 2013; Nyberg et al., 2012). To our knowledge, this is the first report indicating that reduced QSM 
measures of cortical iron-load constitute a lower vulnerability to loss of cognitive function at highest age.  
Amyloid-PET tracers, such as 18F-Flutemetamol (Vandenberghe et al., 2010), have become an 
established approach to estimate regional β-amyloid burden in AD-risk populations. Differences in brain 
structure volumes were investigated by applying a multi-atlas matching approach to T1-MRI data, using 
Likelihood Fusion and Ontology Level Control algorithms, as validated for both healthy and diseased 
study populations (Djamanakova et al., 2014; Tang et al., 2013). Recent efforts in validation of the QSM 
technology made it possible to quantitatively assess regional iron-load in vivo (Deistung et al., 2013; 
Langkammer et al., 2012) and assess iron in a context of neurodegenerative disease (Acosta-Cabronero et 
al., 2013; Ayton et al., 2017; van Bergen et al., 2016a; van Bergen et al., 2016b). When interpreting the 
susceptibility data, it needs to be considered that the iron-load could vary on an inter-voxel basis and that 
QSM is biased by decreased myelin density (Langkammer et al., 2012; Liu et al., 2011). However, the 
cortical and deep gray matter regions investigated in this study are low in myelin content and thus the 
myelin contribution was considered minimal. Distortion by processes of co-registration of PET with MR-
indicators of neuropathological burden or bias due to changes occurring in the time between PET and MR 
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acquisition could be avoided as the respective measures were acquired using an integrated PET-MR 
instrument. 
When investigating the entire study sample, a significant relationship between β-amyloid burden and 
reduced volume resulted, which appears consistent with earlier reports on biomarker-associations in 
populations of older adults at risk for AD (Frisoni et al., 2010; Mormino et al., 2014). Our observation of 
SVCD correlating with β-amyloid burden concurs with earlier ADNI-findings (Guzman et al., 2013). 
Interestingly, we find negative correlations between iron and SVCD throughout the brain - which 
surprised us, as we expected SVCD to be associated with paramagnetic properties due to extravasated 
hemoglobin and vascular pathology. Our SVCD measure did not include the size but only the occurrence 
of WMH as a reflection of incidence of vascular breakdown. As we cannot exclude that an analysis 
focused on WMH-size may provide different results, at this point our findings on SVCD in a context of 
iron need to be interpreted with caution. Additional studies are needed to validate the use of the here-
applied WMH score for assessing SVCD, and also should allow for potential roles of activated microglia 
and iron clearing mechanisms. Our finding of substantial neuropathological burden in the oldest-old is 
consistent with earlier studies on high aged populations (Kawas et al., 2013). In general, reduced 
structural volume and increased β-amyloid burden were more pronounced in the oldest-old than in the 
younger-old, in line with earlier findings of reduced volume as an indicator of incipient 
neurodegeneration and cognitive decline (Dekhtyar et al., 2017; Frisoni et al., 2010; Mormino et al., 
2014). The oldest-old population in our study showed a generally lower cognitive performance than the 
younger-old, which appears consistent with earlier reports on non-pathological cognitive change during 
aging. Oldest-old status in our sample was associated with fewer years of formal education, which reflects 
the lower availability of higher-education in Switzerland during adolescence of the very old participants. 
It is not expected that formal education influence results at this stage of their life, this is supported by the 
lack of correlation between years of education and β-amyloid burden or structure volume. Additionally, 
we only found a non-significant trend regarding the effect of APOE4 status for the odds of being oldest-
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old versus younger-old. This finding could be due to insufficient power in our sample. Alternatively, it 
might be consistent with earlier reports that suggest other factors of brain physiology beyond APOE4 
determine cognitive functioning at a very high age (Corrada et al., 2013; Garibotto et al., 2012). The fact 
that our oldest-old population exhibited a high degree of cognitive functionality despite present 
neuropathology concurs with earlier observations of preserved cognition at highest age (Nyberg et al., 
2012; Rogalski et al., 2013). Considering the well-established relationship between high β-amyloid 
burden and risk for cognitive decline during aging (Jansen et al., 2015), our finding of significantly higher 
β-amyloid burden in cognitively unimpaired oldest-old participants suggests particular resilience against 
neuropathology. Here, our findings of lower iron-load in brain regions implicated in cognitive processes, 
such as the neocortex, posterior cingulate and insula, potentially reflect less neuronal damage. 
Pathological processes that are considered to be reflected by increased local iron-load include oxidative 
stress and presence of activated microglia (Meadowcroft et al., 2009; Nunez et al., 2012; Rottkamp et al., 
2001; Serrano-Pozo et al., 2016; Zeineh et al., 2015). Moreover, increased iron-load is a frequent finding 
in neurodegenerative disease (Andersen et al., 2014; Kruer, 2013). Increased iron-load in basal ganglia 
structures, particularly the putamen, are a known effect of aging (Bartzokis et al., 1997; Hallgren and 
Sourander, 1958) and are consistent with the spatial distribution of our QSM measures of local iron-load. 
Our observation of low cortical iron-load in the cognitively unimpaired oldest-old might thus reflect 
lower vulnerability to age-related neuropathology, and may be consistent with reports of elevated brain 
iron being associated with mild cognitive impairment and liability for AD (Ayton et al., 2015; Ayton et 
al., 2017; Derry and Kent, 2017; van Bergen et al., 2016b). Furthermore, our findings are consistent with 
recently published data on a relationship between increased QSM measures of cerebral iron and β-
amyloid associated cognitive decline (Ayton et al., 2017). 
Several studies have investigated changes to the entorhinal cortex associated with aging and incipient AD, 
as indicated by reduced structural volume (de Leon et al., 1989; Frisoni et al., 2010), and found that 
increased structural volume of memory regions promotes maintained cognitive performance (Dekhtyar et 
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al., 2017; deToledo-Morrell et al., 2004). Thus, while the current clinical study does not provide 
information on neurobiological mechanisms, the here reported positive relationship between entorhinal 
structural volume and β-amyloid plaque-density, which was only observable in the oldest-old, might 
indicate lower vulnerability. However, as entorhinal cortex volumes in the oldest-old did not differ from 
the younger-old, this finding needs to be interpreted with caution. 
Taken together, by investigating a cross-sectional sample of younger- and oldest-old, we 
provide neuroimaging-evidence that low cortical iron-load and high entorhinal volume despite high β-
amyloid burden might characterize individuals less affected by aging-associated neuropathologies. 
Additional translational studies are needed to characterize the interplay between molecular mechanisms 
and genetic disposition that allows for maintained cognitive function at highest age. While our findings 
are consistent with recent reports on low iron burden as a predictor of preserved cognitive functioning in 
older adults (Ayton et al., 2017), therapeutic trials are needed to investigate whether these correlates of 
individual resilience may be exploited for specific disease modifying intervention.   
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Figure captions 
Figure 1) Mean regional average values (SEM) per group for A) volume (ml), B) β-amyloid plaque 
burden (18F-Flutemetamol SUVR). Significant differences after FDR-multiple-testing-correction are 
indicated by * = p < 0.05, ** = p < 0.01 and *** = p < 0.001. 
Figure 2) Mean regional average values (SEM) per group for iron (susceptibility, ppm). Significant 
differences after FDR multiple testing correction are indicated by * = p < 0.05, ** = p < 0.01 and *** = p 
< 0.001.  
Figure 3) Scatterplot for correlations between entorhinal volume (ml) and entorhinal β-amyloid plaque 
burden for oldest-old (r=0.39, p=0.01), younger-old r=-0.09, p=0.59.  
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Table 1: Overview of sample A) demographics and B) neuropsychological test performance measures as mean ± STD. * = 
significant difference (two-sample T-test) between the oldest-old and younger-old with p < 0.05, ** = p < 0.01 and *** = p < 
0.001.  
 Whole sample Younger-old Oldest-old 
A) Demographics    
N (M/F) 80 (54/26) 36 (21/15) 44 (33/11) 
Age 79.20 ± 11.80 67.75 ± 7.75 88.57 ± 2.69 ** 
Education 14.99 ± 2.85 15.92 ± 2.61 14.23 ± 2.84 ** 
ApoE-e4 carriers (%) 17 (21%) 11 (31%) 6 (14%) 
 
   
B) Neuropsychology    
MMSE 28.99 ± 1.10 29.44 ± 0.81 28.60 ± 1.17 ** 
VLMT: delayed recall 7.93 ± 3.99 8.58 ± 3.93 7.43 ± 4.02 ** 
Boston Naming Test 14.43 ± 0.77 14.73 ± 0.45 14.21 ± 0.89 ** 
Trail making test B/A 2.61 ± 1.41 2.17 ± 0.70 2.98 ± 1.71 ** 
CERAD: Word list recall 6.99 ± 1.93 7.79 ± 1.32 6.36 ± 2.12 ** 
CERAD: Word list recognition 9.77 ± 0.65 9.76 ± 0.61 9.78 ± 0.69 
CERAD: Word list learning 8.23 ± 1.39 8.82 ± 0.98 7.76 ± 1.49 ** 
CERAD: Fluency 21.54 ± 6.91 24.36 ± 5.61 19.37 ± 7.08 ** 
Stroop Interference: color-word 32.60 ± 11.26 27.91 ± 7.50 36.48 ± 12.40 ** 
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 Statistics, correlation analysis 
β-amyloid plaque 
burden Iron-load 
A) Regional volume   
Amygdala p=0.01   r=0.28 * p=0.94   r=-0.03 
Insula p=0.99   r=0.00 † p=0.02   r=0.28 * 
Hippocampus p=0.55   r=-0.08 p=0.74   r=0.06 
Entorhinal Cortex p=0.08   r=0.21 † p=0.01   r=-0.30 * 
Frontal Cortex p=0.99   r=0.00 p=0.54   r=0.09 
Temporal Cortex p=0.34   r=0.12 p=0.10   r=0.19 
Parietal Cortex p=0.18   r=-0.16 p=0.03   r=0.26 * 
Occipital Cortex p=0.99   r=-0.02 p=0.68   r=0.06 
Neocortex p=0.90   r=-0.04 p=0.11   r=0.19 
  
B) SVCD-burden (WMH-scores) 
Amygdala p=0.06   r=0.22 p=0.07   r=-0.22 
Insula p=0.07   r=0.22 p=0.42   r=-0.12 
Hippocampus p=0.99   r=0.01 p=0.98   r=0.04 
Entorhinal Cortex p=0.05   r=0.23 * p=0.05   r=-0.24 * 
Frontal Cortex p=0.05   r=0.23 * p=0.06   r=-0.23 
Temporal Cortex p=0.17   r=0.17 p=0.03   r=-0.26 * 
Parietal Cortex p=0.23   r=0.16 p=0.01   r=-0.29 * 
Occipital Cortex p=0.48   r=0.11 p=0.12   r=-0.19 
Neocortex p=0.11   r=0.20 p=0.03   r=-0.26 * 
 
Table 2: Regional correlation analysis for A) volume and B) SVCD with the respective local β-amyloid plaque burden and iron-
load. Indicated are values for the entire sample (n=80), * indicates a significant correlation with p-FDR-corrected < 0.05; † = 
significant differences in regressions slopes between oldest-old and younger-old using Fisher r-to-z transformation, with p < 0.05. 
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 3
 Statistics, pathology-measures by group 
 Whole sample Younger-old Oldest-old 
A) Volume (ml) 
Amygdala 3.19 ± 0.04 3.24 ± 0.05 3.14 ± 0.05 
Insula 11.83 ± 0.12 12.32 ± 0.15 11.44 ± 0.16 *** 
Hippocampus 6.61 ± 0.07 6.95 ± 0.08 6.34 ± 0.08 *** 
Entorhinal Cortex 1.74 ± 0.02 1.72 ± 0.04 1.76 ± 0.03 
Post Cingulate 13.97 ± 0.12 14.18 ± 0.20 13.81 ± 0.15 
Thalamus 8.63 ± 0.08 9.04 ± 0.09 8.29 ± 0.10 *** 
Caudate 6.70 ± 0.08 6.77 ± 0.13 6.65 ± 0.11 
Putamen 6.65 ± 0.07 6.91 ± 0.09 6.44 ± 0.10 ** 
Globus Pallidus 2.46 ± 0.03 2.56 ± 0.04 2.38 ± 0.03 *** 
Frontal Cortex 146.07 ± 0.78 148.31 ± 1.16 144.24 ± 0.97 * 
Temporal Cortex 111.56 ± 0.76 114.40 ± 1.02 109.24 ± 0.97 *** 
Parietal Cortex 76.37 ± 0.45 77.64 ± 0.51 75.33 ± 0.66 * 
B) β-amyloid plaque burden (18F-Flutemetamol SUVR) 
Amygdala 1.37 ± 0.02 1.24 ± 0.02 1.47 ± 0.03 *** 
Insula 1.38 ± 0.04 1.21 ± 0.03 1.52 ± 0.07 *** 
Hippocampus 1.35 ± 0.02 1.28 ± 0.02 1.40 ± 0.03 ** 
Entorhinal Cortex 1.18 ± 0.02 1.08 ± 0.02 1.26 ± 0.03 *** 
Post Cingulate 1.46 ± 0.05 1.31 ± 0.04 1.59 ± 0.08 ** 
Thalamus 1.77 ± 0.03 1.63 ± 0.03 1.88 ± 0.05 *** 
Caudate 1.21 ± 0.04 1.10 ± 0.04 1.30 ± 0.07 * 
Putamen 1.65 ± 0.04 1.47 ± 0.03 1.79 ± 0.06 *** 
Globus Pallidus 2.35 ± 0.04 2.20 ± 0.04 2.48 ± 0.05 *** 
Frontal Cortex 1.32 ± 0.04 1.17 ± 0.04 1.45 ± 0.07 ** 
Temporal Cortex 1.29 ± 0.03 1.17 ± 0.02 1.38 ± 0.05 ** 
Parietal Cortex 1.27 ± 0.04 1.20 ± 0.03 1.33 ± 0.06 
Neocortex 1.30 ± 0.03 1.19 ± 0.03 1.39 ± 0.06 ** 
C) Iron-load (susceptibility, ppm) 
Amygdala 0.022 ± 0.001 0.024 ± 0.002 0.021 ± 0.002 
Insula 0.009 ± 0.001 0.013 ± 0.001 0.005 ± 0.001 *** 
Hippocampus 0.018 ± 0.001 0.018 ± 0.002 0.018 ± 0.001 
Entorhinal Cortex 0.049 ± 0.002 0.050 ± 0.002 0.048 ± 0.003 
Post Cingulate 0.021 ± 0.001 0.023 ± 0.001 0.019 ± 0.001 ** 
Thalamus 0.018 ± 0.001 0.018 ± 0.001 0.018 ± 0.002 
Caudate 0.074 ± 0.003 0.076 ± 0.003 0.073 ± 0.005 
Putamen 0.088 ± 0.004 0.079 ± 0.002 0.096 ± 0.006 * 
Globus Pallidus 0.130 ± 0.004 0.134 ± 0.003 0.128 ± 0.006 
Frontal Cortex 0.023 ± 0.001 0.025 ± 0.001 0.022 ± 0.001 * 
Temporal Cortex 0.021 ± 0.001 0.023 ± 0.001 0.019 ± 0.001 * 
Parietal Cortex 0.026 ± 0.001 0.028 ± 0.001 0.024 ± 0.001 ** 
D) SVCD-burden (WMH-score) 
Whole brain 4.69 ± 1.80 2.36 ± 0.29 6.59 ± 0.62 ** 
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Supplementary Table 1: Overview of average structure volume, β-amyloid plaque burden, iron-load and WHM-scores per region 
and group (mean ± SEM). Group-differences were investigated by independent-sample, two tailed T-test and FDR correction for 
multiple testing * = p < 0.05, ** = p < 0.01 and *** = p < 0.001. 
 
 
 Whole sample Younger-old Oldest-old 
A) Volume (ml)    
Amygdala p=0.09   r=-0.21 p=0.68   r=-0.15 p=0.62   r=-0.14 
Insula p=0.15   r=-0.19 p=0.99   r=0.04 p=0.52   r=-0.16 
Hippocampus p=0.29   r=-0.15 p=0.09   r=-0.21 p=0.94   r=0.09 
Entorhinal Cortex p=0.07   r=-0.21 p=0.55   r=-0.17 p=0.92   r=-0.09 
Post Cingulate p=0.19   r=-0.18 p=0.99   r=0.08 p=0.35   r=-0.19 
Thalamus p=0.33   r=-0.15 p=0.92   r=0.11 p=0.83   r=-0.11 
Caudate p=0.16   r=-0.19 p=0.99   r=0.00 p=0.32   r=-0.20 
Putamen p=0.23   r=-0.17 p=0.66   r=0.15 p=0.55   r=-0.15 
Globus Pallidus p=0.25   r=-0.16 p=0.99   r=-0.07 p=0.99   r=-0.04 
Frontal Cortex p=0.14   r=-0.20 p=0.99   r=0.01 p=0.42   r=-0.18 
Temporal Cortex p=0.15   r=-0.19 p=0.99   r=0.01 p=0.46   r=-0.17 
Parietal Cortex p=0.19   r=-0.18 p=0.99   r=0.02 p=0.28   r=-0.21 
Neocortex p=0.13   r=-0.20 p=0.99   r=-0.02 p=0.40   r=-0.18 
B) β-amyloid plaque burden (18F-Flutemetamol SUVR) 
Amygdala p=0.99   r=0.03 p=0.90   r=-0.11 p=0.99   r=0.04 
Insula p=0.68   r=0.10 p=0.99   r=-0.06 p=0.99   r=-0.03 
Hippocampus p=0.99   r=0.04 p=0.86   r=-0.11 p=0.36   r=-0.19 
Entorhinal Cortex p=0.50   r=0.12 p=0.09   r=0.13 p=0.99   r=0.00 
Post Cingulate p=0.12   r=0.20 p=0.52   r=0.18 p=0.60   r=0.14 
Thalamus p=0.43   r=0.13 p=0.17   r=-0.21 p=0.83   r=0.11 
Caudate p=0.99   r=0.04 p=0.70   r=-0.14 p=0.66   r=0.13 
Putamen p=0.27   r=0.16 p=0.99   r=0.08 p=0.99   r=0.03 
Globus Pallidus p=0.45   r=0.13 p=0.99   r=0.01 p=0.99   r=0.00 
Frontal Cortex p=0.28   r=0.16 p=0.99   r=0.03 p=0.86   r=0.10 
Temporal Cortex p=0.38   r=0.14 p=0.57   r=0.16 p=0.92   r=-0.10 
Parietal Cortex p=0.99   r=0.06 p=0.99   r=0.08 p=0.88   r=-0.10 
Neocortex p=0.17   r=0.19 p=0.59   r=0.16 p=0.74   r=-0.12 
 
Supplementary Table 2: Regional correlation between years of education and A) structure volume and B) local β-amyloid plaque 
burden. 
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Highlights 
• Combined PET-MRI was used to investigate maintained cognition at highest age 
• QSM measures of cortical iron load were lower in cognitively unimpaired oldest-old 
• Low cortical iron constitutes low vulnerability to aging-associated neuropathologies 
• In the oldest-old, high entorhinal cortex volume was associated with high β-Amyloid 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
All authors contributed to and have approved the final manuscript. All sources of funding and personal 
relationships relevant to this study are disclosed. None of the authors has published or submitted any 
related papers from the same study.  
Competing Financial Interests statement 
Dr. Peter van Zijl is a paid lecturer for Philips Healthcare and is the inventor of technology that is licensed 
to Philips. This arrangement has been approved by The Johns Hopkins University in accordance with its 
Conflict of Interest policies. Dr. Paul G. Unschuld is supported by a GE-healthcare grant for investigator 
initiated research. This funding is in accordance with guidelines issued by the University of Zürich. 
Acknowledgments 
We thank all subjects for their study participation and Esmeralda Gruber for help with patient recruitment 
and study administration. This work was funded by the Swiss National Science Foundation 
(Schweizerischer Nationalfonds, SNF), the Mäxi foundation, the Clinical Research Priority Program 
(CRPP) of the University of Zürich on Molecular Imaging (MINZ), a grant from the National Institutes of 
Health (NIBIB) P41 EB015909, investigator initiated research support by GE-healthcare (114-2014-IIR-
0075 and 114-2014-IIR-0076), and institutional support from the Institute for Regenerative Medicine 
(IREM), University of Zürich, Switzerland. This work was supported by the Zürich Impulse Program for 
the Sustainable Development of Mental Health Services. 
 
